Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30594197 | 0.89 | CYP4F2 (0.55) | CYP4F2CYP4A11ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2432961 | 0.89 | CYP4F2 (0.55) | CYP4F2CYP4A11ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL491276 | 0.87 | CYP4F2 (0.59) | CYP4F2CYP4A11LMNASMN1; SMN2 | |
| SCHEMBL8912630 | 0.85 | CYP4F2 (0.58) | CYP4F2CYP4A11ALOX5OR51E2ALDH1A1 | |
| SCHEMBL22070576 | 0.85 | FFAR1 (0.48) | CYP4F2CYP4A11ALDH1A1LMNA | |
| SCHEMBL6913578 | 0.85 | CYP4F2 (0.61) | CYP4F2CYP4A11ALDH1A1 | |
| Dihydroferulic Acid Ethyl Ester SCHEMBL356300 | 0.84 | ALOX5 (0.67) | CYP4F2CYP4A11ALOX5OR51E2ALDH1A1 | |
| SCHEMBL8364365 | 0.84 | CYP4F2 (0.59) | CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL17295176 | 0.83 | CYP4F2 (0.55) | CYP4F2CYP4A11ALOX5OR51E2ALDH1A1 | |
| SCHEMBL5685284 | 0.83 | CALM1 (0.57) | CYP4F2CYP4A11ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217027-B2 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217027-B2 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217027-B2 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| CN-101610674-A | Sphingosine-1-phosphate ester receptor stimulating agent and agonist compounds | ABBOTT LAB (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-2120575-A1 | SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS | Abbott Laboratories (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBVIE INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBVIE INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | ABBVIE INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008079382-A1 | SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079382-A1 | SPHINGOSINE-1 -PHOSPHATE RECEPTOR AGONIST AND ANTAGONIST COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029947-A1 | Sphingosine-1-phosphate receptor agonist and antagonist compounds | S1PR1, S1PR3, S1PR5 | CYP4F2 3622/4885CYP4A11 1896/4885ALOX5 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.